We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
251
DELISTED
Blueprint Medicines
BPMC
| $9.56M | 0.07% |
151,222
-302,790
| -67% | -$16.5M |
|
252
KLA
KLAC
$266B
| $9.4M | 0.07% |
193,740
-79,800
| -29% | -$3.33M |
|
253
Liberty Media Series C
FWONK
$24.6B
| $9.24M | 0.07% |
127,015
+96,095
| +311% | +$6.83M |
|
254
Cogent Biosciences
COGT
$6.91B
| $9.15M | 0.07% |
772,487
-164,654
| -18% | -$1.89M |
|
255
DexCom
DXCM
$28.3B
| $9.07M | 0.07% |
70,614
+12,586
| +22% | +$1.52M |
|
256
ResMed
RMD
$29.5B
| $8.98M | 0.06% |
41,103
-14,425
| -26% | -$3.22M |
|
257
Apollo Global Management
APO
$71.6B
| $8.93M | 0.06% |
116,318
+49,088
| +73% | +$3.28M |
|
258
Herc Holdings
HRI
$5.34B
| $8.93M | 0.06% |
65,247
+49,965
| +327% | +$5.53M |
|
259
Everest Group
EG
$15.4B
| $8.78M | 0.06% |
25,673
-11,612
| -31% | -$4.19M |
|
|
FOLD
260
DELISTED
Amicus Therapeutics
FOLD
| $8.72M | 0.06% |
693,879
| – | – |
|
261
Vir Biotechnology
VIR
$1.48B
| $8.7M | 0.06% |
+354,645
| New | +$8.91M |
|
262
ITT
ITT
$17.7B
| $8.48M | 0.06% |
90,997
+40,842
| +81% | +$3.43M |
|
263
Intel
INTC
$462B
| $8.45M | 0.06% |
252,752
-598,863
| -70% | -$18.8M |
|
264
Krystal Biotech
KRYS
$10.4B
| $8.22M | 0.06% |
70,000
-22,000
| -24% | -$2.25M |
|
265
Shopify
SHOP
$165B
| $8.16M | 0.06% |
126,181
+31,099
| +33% | +$1.76M |
|
266
Dyne Therapeutics
DYN
$4.24B
| $8.14M | 0.06% |
723,624
+90,000
| +14% | +$1.06M |
|
267
Clearway Energy Class C
CWEN
$5B
| $8.14M | 0.06% |
284,861
+4,614
| +2% | +$139K |
|
|
ITOS
268
DELISTED
iTeos Therapeutics
ITOS
| $8.1M | 0.06% |
611,547
-127,970
| -17% | -$1.82M |
|
269
Dell
DELL
$276B
| $8.09M | 0.06% |
149,580
+4,705
| +3% | +$217K |
|
270
Bruker
BRKR
$9.14B
| $8.07M | 0.06% |
109,186
-169,000
| -61% | -$12.9M |
|
271
Schrodinger
SDGR
$1.14B
| $7.99M | 0.06% |
160,000
-30,000
| -16% | -$1.01M |
|
|
MRSN
272
DELISTED
Mersana Therapeutics
MRSN
| $7.95M | 0.06% |
96,619
-21,895
| -18% | -$3.2M |
|
273
Arrowhead Research
ARWR
$12B
| $7.85M | 0.06% |
220,054
-68,000
| -24% | -$2.34M |
|
274
Kite Realty
KRG
$5.99B
| $7.83M | 0.06% |
350,468
-408,707
| -54% | -$8.43M |
|
|
NEWR
275
DELISTED
New Relic, Inc.
NEWR
| $7.81M | 0.06% |
+119,418
| New | +$8.61M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.